ALNEV.PA Stock - Neovacs S.A.
Unlock GoAI Insights for ALNEV.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $366,346 | $533,412 | $1,112 | $22,595 | $29,784 |
| Gross Profit | $42,421 | $-6,754,358 | $-6,260,979 | $-7,596,551 | $-3,391,922 |
| Gross Margin | 11.6% | -1266.3% | -563037.7% | -33620.5% | -11388.4% |
| Operating Income | $-6,764,344 | $-6,907,549 | $-6,444,966 | $-7,839,538 | $-3,492,882 |
| Net Income | $-32,914,409 | $-8,743,450 | $-3,548,503 | $-11,837,302 | $-6,142,660 |
| Net Margin | -8984.5% | -1639.2% | -319110.0% | -52389.0% | -20624.0% |
| EPS | $-188.61 | $-249000.00 | $-1.18 | $-4720000000000.00 | $-72960000000000.00 |
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Visit WebsiteEarnings History & Surprises
ALNEV.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Dec 31, 2024 | — | $-11.02 | — | — |
Q2 2024 | Jun 30, 2024 | — | $-33192.52 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-126829.52 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-306370171.67 | — | — |
Q4 2022 | Dec 31, 2022 | — | — | — | — |
Q2 2022 | Jun 30, 2022 | — | — | — | — |
Q4 2019 | Dec 31, 2019 | — | — | — | — |
Q4 2019 | Oct 3, 2019 | — | — | — | — |
Q2 2019 | Jun 30, 2019 | — | — | — | — |
Q1 2019 | Mar 25, 2019 | — | — | — | — |
Q4 2018 | Dec 31, 2018 | — | — | — | — |
Q4 2018 | Oct 30, 2018 | — | — | — | — |
Q2 2018 | Jun 30, 2018 | — | — | — | — |
Q1 2018 | Mar 30, 2018 | — | — | — | — |
Q4 2017 | Dec 31, 2017 | — | — | — | — |
Q4 2017 | Oct 27, 2017 | — | — | — | — |
Q2 2017 | Jun 30, 2017 | — | — | — | — |
Q1 2017 | Mar 30, 2017 | — | — | — | — |
Q4 2016 | Dec 31, 2016 | — | — | — | — |
Q4 2016 | Oct 11, 2016 | — | — | — | — |
Latest News
Frequently Asked Questions about ALNEV.PA
What is ALNEV.PA's current stock price?
What is the analyst price target for ALNEV.PA?
What sector is Neovacs S.A. in?
What is ALNEV.PA's market cap?
Does ALNEV.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALNEV.PA for comparison